Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Acquired resistance to cancer therapies is a significant clinical challenge.
• Cervical cancer, particularly advanced stages, exhibits high recurrence rates due to drug resistance.
• Investigating resistance mechanisms in vitro is crucial for developing effective treatments.

Purpose of the Study:

• To generate novel cervical cancer cell lines with acquired resistance to a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
• To characterize the molecular and phenotypic changes associated with drug resistance in these cell lines.
• To provide valuable tools for studying drug resistance mechanisms and identifying potential biomarkers.

Main Methods:

• Development of drug-resistant (DR) cell lines from HeLa, CaSki, and SiHa cervical cancer cell lines using PD173074 (an FGFR tyrosine kinase inhibitor).
• Analysis of protein expression (FGFR1, FGFR2, FGF2, FGF4, FGF7) and localization in parental and DR cell lines.
• Assessment of phenotypic characteristics, including migration, proliferation, and apoptosis, in parental and DR cells.

Main Results:

• Three novel, robust cervical cancer cell lines (HeLa, CaSki, SiHa) acquired resistance to PD173074.
• DR cell lines exhibited overexpression and nuclear localization of FGFR1, FGFR2, FGF2, FGF4, and FGF7.
• DR cells displayed a significantly more aggressive phenotype: increased migration and proliferation, and decreased apoptosis.

Conclusions:

• The novel drug-resistant cervical cancer cell lines are essential tools for understanding acquired resistance mechanisms.
• These cell lines can facilitate the identification of biomarkers for cervical cancer.
• The availability of these models may aid in developing combination therapies targeting FGFR pathways and resistance mechanisms.